Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and response to treatment at the individual level.
Objective
To investigate whether patient characteristics differ across biologics for patients initiating biologic therapy and for patients still on biologic therapy after 1 year. Also, to quantify and compare the use of topical therapy among patients still on biologic therapy after 1 year.
Methods
This nationwide cohort study compared characteristics of patients prescribed adalimumab, etanercept, infliximab, secukinumab or ustekinumab for treatment of psoriasis by using data from the Danish registries.
Results
In the ustekinumab group, patients were younger and fewer had psoriatic arthritis. Patients treated with secukinumab and ustekinumab were less frequently co-treated with conventional systemics and topical therapy. All other patient characteristics such as sex, smoking and comorbidities other than psoriatic arthritis were similar across the biologic cohorts.
Conclusion
These results highlight the need to better understand which factors to consider when prescribing biologics to patients with psoriasis.
ParisiRIskandarIYKKontopantelisEAugustinMGriffithsCEMAshcroftDM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi:10.1136/bmj.m1590.
2.
AlinaghiFCalovMKristensenLE, et al.Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265. doi:10.1016/j.jaad.2018.06.027.
3.
SajjaAPJoshiAATeagueHLDeyAKMehtaNN. Potential immunological links between psoriasis and cardiovascular disease. Front Immunol. 2018;9:1234. doi:10.3389/fimmu.2018.01234.
4.
BoehnckeWH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi:10.3389/fimmu.2018.00579.
5.
EgebergASkovLJoshiAA, et al.The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650-656. doi:10.1016/j.jaad.2017.06.028.
6.
FuYLeeCHChiCC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417-1427. doi:10.1001/jamadermatol.2018.3631.
7.
JensenPSkovL. Psoriasis and obesity. Dermatology. 2016;232(6):633-639. doi:10.1159/000455840.
8.
KaushikSBLebwohlMG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27-40. doi:10.1016/j.jaad.2018.06.057.
9.
LoftNEgebergARasmussenMK, et al.Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol. 2021;157(6):676-683. doi:10.1001/JAMADERMATOL.2021.0221.
10.
TarganSRFeaganBVermeireS, et al.A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016;111(11):1599-1607. doi:10.1038/ajg.2016.298.
11.
LoftNDVaengebjergSHallingASSkovLEgebergA. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020;34(6):1151-1160. doi:10.1111/jdv.16073.
12.
WarrenRBMarsdenATomensonB, et al.Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069-1076. doi:10.1111/bjd.16776.
13.
PinterAGerdesSPapavassilisCReinhardtM. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatolog Treat. 2020;31(8):769-775. doi:10.1080/09546634.2019.1626973.
14.
García-DovalIPérez-ZafrillaBFerrandizC, et al.Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. J Dermatolog Treat. 2016;27(3):203-209. doi:10.3109/09546634.2015.1088130.
15.
SchwarzCWLoftNRasmussenMK, et al.Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol. 2021;101(10):adv00579. doi:10.2340/actadv.v101.351.
16.
von ElmEAltmanDGEggerMPocockSJGøtzschePCVandenbrouckeJP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X.
17.
SchmidtMSchmidtSAJSandegaardJLEhrensteinVPedersenLSørensenHT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490. doi:10.2147/CLEP.S91125.
18.
PottegårdASchmidtSAJWallach-KildemoesHSørensenHTHallasJSchmidtM. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798-799. doi:10.1093/ije/dyw213.
19.
SchmidtMPedersenLSørensenHT. The Danish Civil registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549. doi:10.1007/s10654-014-9930-3.
20.
EgebergAMallbrisLGislasonGHSkovLHansenPR. Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol. 2016;136(1):93-98. doi:10.1038/JID.2015.350.
21.
EgebergAHansenPRGislasonGHSkovLMallbrisL. Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2016;175(3):493-500. doi:10.1111/bjd.14633.
22.
McHughML. The chi-square test of independence. Biochem Med. 2013;23(2):143-149. doi:10.11613/bm.2013.018.
23.
SbidianEChaimaniAGarcia-DovalI, et al.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535. doi:10.1002/14651858.CD011535.pub5.
24.
YenHHuangCHHuangIH, et al.Systematic review and critical appraisal of psoriasis clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP). Br J Dermatol. 2022;187(2):178-187. doi:10.1111/BJD.21047.
25.
NastASmithCSpulsPI, et al.EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281-317. doi:10.1111/JDV.16926.
26.
NastASmithCSpulsPI, et al.EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281-317. doi:10.1111/JDV.16926.
27.
SbidianEGiboinCBachelezH, et al.Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. J Eur Acad Dermatol Venereol. 2017;31(12):2046-2054. doi:10.1111/JDV.14406.
28.
LoftNEgebergARasmussenMK, et al.Response to biologics during the first six months of therapy in biologic-naïve patients with psoriasis predicts risk of disease flares: a Danish nationwide study. Acta Derm Venereol. 2021;101(1):adv00357. doi:10.2340/00015555-3722.
ReichKBlauveltAArmstrongA, et al.Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019;33(9):1733-1741. doi:10.1111/JDV.15637.
31.
JaniMBartonAWarrenRBGriffithsCEMChinoyH. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53(2):213. doi:10.1093/RHEUMATOLOGY/KET260.
32.
HäggDSundströmAErikssonMSchmitt-EgenolfM. Severity of psoriasis differs between men and women: a study of the clinical outcome measure psoriasis Area and severity Index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol. 2017;18(4):583-590. doi:10.1007/S40257-017-0274-0.
33.
WaljeeAKHigginsPDRJensenCB, et al.Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(3):276-284. doi:10.1016/S2468-1253(19)30362-0.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
